PDCD1 and head and neck squamous cell carcinoma: Another phase III clinical trial (NCT04146402) evaluated the efficacy and safety of finotonlimab (SCT-I10A), a PD-1 monoclonal antibody, combined with cisplatin plus 5-FU (abbreviated further in combination as C5F) as a first-line treatment for R/M-HNSCC in an Asian population.